Shire’s Mesavance User Fee Date Extended To Jan. 21
Delay allows FDA to review supplemental Phase I dose absorption study for ulcerative colitis treatment.
Delay allows FDA to review supplemental Phase I dose absorption study for ulcerative colitis treatment.